Oscotec Inc

Oscotec Inc. is a clinical-stage drug discovery and development company. Its pipeline includes a SYK inhibitor in Phase IIa for rheumatoid arthritis and immune thrombocytopenia, an FLT3 inhibitor in Phase I for acute myeloid leukemia, an EGFR double mutation inhibitor for non-small cell lung cancer, and an anti-Tau antibody in preclinical phase for Alzheimer's disease. The company also offers dental health products, including bone grafts (InduCera, BioCera-F, SynCeraII) and membranes (LysoGide, CollaGuide), as well as functional ingredients such as OPB for osteoporosis, AIF for arthritis, SGA for bone growth, and PRF-K for periodontal diseases. Formerly known as Oscotec Co., Ltd., it changed its name to Oscotec Inc. in June 1999, was founded in 1988, and is based in Seongnam, South Korea.